Hsu-Ping Kuo

Title: Hsu-Ping Kuo: Innovator in B-Cell Malignancy Treatment

Introduction

Hsu-Ping Kuo is a notable inventor based in Sunnyvale, CA (US). He has made significant contributions to the field of oncology, particularly in the treatment of B-cell malignancies. His innovative work has led to the development of important therapeutic combinations that enhance treatment efficacy.

Latest Patents

Hsu-Ping Kuo holds 1 patent for his invention titled "Bruton's tyrosine kinase inhibitor combinations and uses thereof." This patent discloses methods, compositions, and kits for treating B-cell malignancies by administering a combination of a BTK inhibitor, such as ibrutinib, and a PIM inhibitor. Additionally, it addresses treatment strategies for BTK-resistant B-cell malignancies using similar combinations.

Career Highlights

Throughout his career, Hsu-Ping Kuo has worked with prominent companies in the pharmaceutical industry. He has been associated with Janssen Pharmaceutica and Pharmacyclics, where he contributed to the advancement of cancer therapies. His expertise in drug development has been instrumental in creating effective treatment options for patients.

Collaborations

Hsu-Ping Kuo has collaborated with esteemed colleagues, including Hsin-Kang Hsieh and Sriram Balasubramanian. These partnerships have fostered innovation and have been crucial in the research and development of new therapeutic strategies.

Conclusion

Hsu-Ping Kuo's contributions to the field of oncology through his patent and collaborations highlight his role as a key innovator in the treatment of B-cell malignancies. His work continues to impact the lives of patients facing these challenging conditions.